Slide 1: FY20 Results
For personal use only A L E A D I N G E N T E R P R I S E I M A G I N G S O F T W A R E P R O V I D E R F O R H E A LT H C A R E FY20 RESULTS 27 August 2020 Approved for Release to ASX by Board of Directors
Slide 2: Disclaimer 'Forward-looking' Statements
DISCLAIMER ‘FORWARD-LOOKING’ STATEMENTS For personal use only Summary of information: This presentation contains general and background information about Mach7 performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of Technologies Limited (“M7T”)
Slide 3: Mach7 Global Complete Enterprise Imaging Platform
MACH7 GLOBAL COMPLETE ENTERPRISE IMAGING PLATFORM ENTERPRISE • eUnity enterprise viewer (front-end) For personal use only • Mach7 Platform with VNA and workflows (back-end) IMAGING LEADER ASX:M7T GLOBAL CUSTOMER BASE • Market Cap $245M (235m shares • North America on issue) • Asia • Qatar • Europe G
Slide 4: Mach7 Growth Path
MACH7 GROWTH PATH For personal use only 2007 2010 2012 2016 2018 2019 2020 Mach7 Founded • First Pilots Deployed • First Commercial Wins Listed on ASX (M7T) New Diagnostic, • Completes Client • Cloud Deployments • Revenue Phase Begins Connected Health Outlook Acquisition • USA & Middle East and AI S
Slide 5: Financial Highlights – FY20
FINANCIAL HIGHLIGHTS – FY20 For personal use only REVENUES EBITDA POSITIVE Up to $18.9m Up to $3.3m FREE CASH FLOW +102% 20.0 M +181% +264% Up to $4.7m 18.0 M 16.0 M 6.0 M 14.0 M 5.0 M 12.0 M 4.0 M 4.0 M 10.0 M 3.0 M 2.0 M 2.0 M 8.0 M 6.0 M 0.0 M 1.0 M 0.0 M 4.0 M (2.0 M) (1.0 M) 2.0 M (2.0 M) 0.0 M
Slide 6: Financial Highlights – FY20
FINANCIAL HIGHLIGHTS – FY20 For personal use only CARR SALES ORDERS (FYV) (Contracted Annual Up to $13.3m +14% Recurring Revenue) +115% Up to $9m 14.00 13.28 Millions 12.00 10,000,000 10.00 7.75 8,000,000 8.00 6.19 6.00 6,000,000 4.00 4,000,000 2.00 2.16 0.00 0.83 0.62 2,000,000 FY18 FY19 FY20 0 Fir
Slide 7: Business Highlights – FY20
BUSINESS HIGHLIGHTS – FY20 For personal use only BUSINESS ACQUISITION OF ENHANCED PRODUCT FURTHER CLIENT OUTLOOK, LEADERSHIP INNOVATION DE-RISKED INC. CAPABILITY • First of it’s kind • QUALITY: Profitability • Acquired Canadian-based • Rob Bazzani joins the Board of Cardiology Integration and positi
Slide 8: Update on Client Outlook/Mach7 Integration
UPDATE ON CLIENT OUTLOOK/MACH7 INTEGRATION For personal use only IMMEDIATE INTEGRATION SYNERGIES OPTIMIZATION TRANSFORMATION I dentify AU$2M in cost I m prove how w e do OBJECTIVE “One M ach7” Transform our Business consolidation opportunities Business • Integrated Sales, • Future-state org structur
Slide 9: Customers – FY20
CUSTOMERS – FY20 For personal use only NEW AND EXPANDED GLOBAL SUCCESSFUL CUSTOMER DEPLOYMENTS CUSTOMER DEALS Nine (9) successful customer deployments, contributing $2.0M (p.a.) Sales orders of $13.3M (first year value “FYV”), in annual recurring revenue commencing FY20 ($1M recognised with $2.2M of
Slide 10: COVID-19 Update
COVID-19 UPDATE For personal use only DEMAND FOR MACH7 SALES CYCLE HAS NEW MARKET SOFTWARE CONTINUES LENGTHENED SINCE MAR 2020 OPPORTUNITY FOR • Expected pent-up demand for • COVID-19 has created tremendous short- MACH7 SOFTWARE ARISES software that will assist with term impacts on the healthcare in
Slide 11: Sales Pipeline
SALES PIPELINE For personal use only Sales pipeline remains strong (despite COVID-19) • 8 x Active RFP’s. Since last investor presentation (May 2020): 1 x Won (HMC US$2.75M support contract) 0 x Lost • 2 x RFP’s “Vendor of Choice” to be awarded by December 2020 FY20 RESULTS | AUG 2020 | 11
Slide 12: Product Suite
PRODUCT SUITE For personal use only VENDOR NEUTRAL COMMUNICATION UNIVERSAL eUNITY VIEWER ARCHIVE (VNA) WORKFLOW ENGINE WORKLIST • One zero footprint • Single platform enables (CWE) • Enables Radiologists to read viewing platform for all users & devices customer to integrate all images from anywhere
Slide 13: Our 12-Month Plan
OUR 12-MONTH PLAN For personal use only INTEGRATE CUSTOMER FOCUS INNOVATE • All Sales and Marketing functions • New leader in place Brenda Rankin to • Release of v12 which will be a new working from the same CRM lead all customer efforts design of our Management Studio • All customer facing departme
Slide 14: FY21 and Beyond
FY21 AND BEYOND For personal use only WELL POSITIONED FOR FOCUSED ON DELIVERING FURTHER REVENUE GROWTH PROFITABLE GROWTH • Recent entry into the PACS market with full enterprise imaging • Continue strong double-digit revenue growth product suite – Mach7 + eUnity • Grow EBITDA (FY20 $3.3M) • Sales &
Slide 15: Investment Thesis
INVESTMENT THESIS For personal use only MED-TECH-THEMATIC • No obvious ASX alternative for pure exposure to Enterprise Imaging STRONG FINANCIALS • Disruptive • High Proportion of Technology QUALITY BUSINESS PENDING CATALYSTS Recurring Revenue PROVEN TECH • Profitable and free cash • Complete integra
Slide 16: Thank You
THANK YOU For personal use only MIKE LAMPRON Managing Director Mike.Lampron@mach7t.com +1 845 5547277 JENNI PILCHER A NEW ERA IN ENTERPRISE IMAGING I N N O VATI O N A N D IN D E P E N D E N C E CFO, Company Secretary Jenni.Pilcher@mach7t.com +61 424 750737